These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25634912)

  • 1. Progestin-Containing Contraceptives Alter Expression of Host Defense-Related Genes of the Endometrium and Cervix.
    Goldfien GA; Barragan F; Chen J; Takeda M; Irwin JC; Perry J; Greenblatt RM; Smith-McCune KK; Giudice LC
    Reprod Sci; 2015 Jul; 22(7):814-28. PubMed ID: 25634912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical and systemic concentrations of long acting hormonal contraceptive (LARC) progestins depend on delivery method: Implications for the study of HIV transmission.
    Buckner LR; Drobnis EZ; Augustine MS; Rogers LK; Akers J; Mott PD; Hope TJ; Quayle AJ; Schust DJ
    PLoS One; 2019; 14(5):e0214152. PubMed ID: 31095572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of fractalkine and its receptor in normal human endometrium and in endometrium from users of progestin-only contraception supports a role for fractalkine in leukocyte recruitment and endometrial remodeling.
    Hannan NJ; Jones RL; Critchley HO; Kovacs GJ; Rogers PA; Affandi B; Salamonsen LA
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6119-29. PubMed ID: 15579768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies.
    Apter D; Gemzell-Danielsson K; Hauck B; Rosen K; Zurth C
    Fertil Steril; 2014 Jun; 101(6):1656-62.e1-4. PubMed ID: 24726226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase-1 and -3 and mast cells are present in the endometrium of women using progestin-only contraceptives.
    Vincent AJ; Zhang J; Ostor A; Rogers PA; Affandi B; Kovacs G; Salamonsen LA
    Hum Reprod; 2000 Jan; 15(1):123-30. PubMed ID: 10611200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the levonorgestrel-containing intrauterine device, copper intrauterine device, and levonorgestrel-containing oral contraceptive on susceptibility of immune cells from cervix, endometrium and blood to HIV-1 fusion measured ex vivo.
    Cavrois M; Hilton JF; Roan NR; Takeda M; Seidman D; Averbach S; Chang E; Raman N; Greenblatt R; Shacklett BL; Smith-McCune K
    PLoS One; 2019; 14(8):e0221181. PubMed ID: 31437197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential elevation of matrix metalloproteinase expression in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time.
    Labied S; Galant C; Nisolle M; Ravet S; Munaut C; Marbaix E; Foidart JM; Frankenne F
    Hum Reprod; 2009 Jan; 24(1):113-21. PubMed ID: 18812421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestin-releasing intrauterine systems.
    Luukkainen T; Pakarinen P; Toivonen J
    Semin Reprod Med; 2001 Dec; 19(4):355-63. PubMed ID: 11727177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
    Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
    Arnes M; Hvingel B; Orbo A
    Anticancer Res; 2014 May; 34(5):2319-24. PubMed ID: 24778038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users.
    Li A; Felix JC; Yang W; Jain JK
    Fertil Steril; 2008 Sep; 90(3):872-5. PubMed ID: 18155704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature.
    Simbar M; Tehrani FR; Hashemi Z; Zham H; Fraser IS
    J Fam Plann Reprod Health Care; 2007 Oct; 33(4):271-6. PubMed ID: 17925114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate.
    Jain JK; Li A; Yang W; Minoo P; Felix JC
    Hum Reprod; 2006 Mar; 21(3):798-809. PubMed ID: 16311300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of the levonorgestrel-releasing intrauterine system (Mirena) and depot-medroxyprogesterone acetate (Depo-Provera) on subendometrial microvascularisation and uterine artery blood flow.
    Dane B; Akca A; Dane C; Evcimen S; Cetin A
    Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):240-4. PubMed ID: 19565422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
    van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.
    Ismail MT; Fahmy DM; Elshmaa NS
    Reprod Sci; 2013 Jan; 20(1):45-50. PubMed ID: 23203322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an animal experimental model to study the effects of levonorgestrel on the human endometrium.
    Alvarez Gonzalez ML; Galant C; Frankenne F; Nisolle M; Labied S; Foidart JM; Marbaix E; Béliard A
    Hum Reprod; 2009 Mar; 24(3):697-704. PubMed ID: 19095670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.